113 related articles for article (PubMed ID: 26742637)
41. Valproic Acid Protects Primary Dopamine Neurons from MPP
Zhang C; Yuan X; Hu Z; Liu S; Li H; Wu M; Yuan J; Zhao Z; Su J; Wang X; Liao Y; Liu Q
Biomed Res Int; 2017; 2017():8124501. PubMed ID: 28421199
[TBL] [Abstract][Full Text] [Related]
42. Six psychotropics for pre-symptomatic & early Alzheimer's (MCI), Parkinson's, and Huntington's disease modification.
Lauterbach EC
Neural Regen Res; 2016 Nov; 11(11):1712-1726. PubMed ID: 28123400
[TBL] [Abstract][Full Text] [Related]
43. The Proteasome Inhibition Model of Parkinson's Disease.
Bentea E; Verbruggen L; Massie A
J Parkinsons Dis; 2017; 7(1):31-63. PubMed ID: 27802243
[TBL] [Abstract][Full Text] [Related]
44. Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.
Masilamoni GJ; Smith Y
J Neural Transm (Vienna); 2018 Mar; 125(3):337-363. PubMed ID: 28861737
[TBL] [Abstract][Full Text] [Related]
45. Reactive astrocytes are key players in nigrostriatal dopaminergic neurorepair in the MPTP mouse model of Parkinson's disease: focus on endogenous neurorestoration.
'Episcopo FL; Tirolo C; Testa N; Caniglia S; Morale MC; Marchetti B
Curr Aging Sci; 2013 Feb; 6(1):45-55. PubMed ID: 23895521
[TBL] [Abstract][Full Text] [Related]
46. Associated degeneration of ventral tegmental area dopaminergic neurons in the rat nigrostriatal lactacystin model of parkinsonism and their neuroprotection by valproate.
Harrison IF; Anis HK; Dexter DT
Neurosci Lett; 2016 Feb; 614():16-23. PubMed ID: 26742637
[TBL] [Abstract][Full Text] [Related]
47. The histone deacetylase inhibitor nicotinamide exacerbates neurodegeneration in the lactacystin rat model of Parkinson's disease.
Harrison IF; Powell NM; Dexter DT
J Neurochem; 2019 Jan; 148(1):136-156. PubMed ID: 30269333
[TBL] [Abstract][Full Text] [Related]
48. Different effects of intranigral and intrastriatal administration of the proteasome inhibitor lactacystin on typical neurochemical and histological markers of Parkinson's disease in rats.
Lorenc-Koci E; Lenda T; Antkiewicz-Michaluk L; Wardas J; Domin H; Smiałowska M; Konieczny J
Neurochem Int; 2011 Jun; 58(7):839-49. PubMed ID: 21419185
[TBL] [Abstract][Full Text] [Related]
49. Proteasome inhibitors protect against degeneration of nigral dopaminergic neurons in hemiparkinsonian rats.
Inden M; Kondo J; Kitamura Y; Takata K; Nishimura K; Taniguchi T; Sawada H; Shimohama S
J Pharmacol Sci; 2005 Feb; 97(2):203-11. PubMed ID: 15684568
[TBL] [Abstract][Full Text] [Related]
50. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
[TBL] [Abstract][Full Text] [Related]
51. Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up-regulation of neurotrophic factors.
Harrison IF; Crum WR; Vernon AC; Dexter DT
Br J Pharmacol; 2015 Aug; 172(16):4200-15. PubMed ID: 26040297
[TBL] [Abstract][Full Text] [Related]
52. Pedunculopontine cell loss and protein aggregation direct microglia activation in parkinsonian rats.
Elson JL; Yates A; Pienaar IS
Brain Struct Funct; 2016 May; 221(4):2319-41. PubMed ID: 25989851
[TBL] [Abstract][Full Text] [Related]
53. Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA.
Konieczny J; Czarnecka A; Kamińska K; Lenda T; Nowak P
Behav Brain Res; 2015 Apr; 283():203-14. PubMed ID: 25655509
[TBL] [Abstract][Full Text] [Related]
54. Chronic L-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the rat substantia nigra.
Konieczny J; Czarnecka A; Lenda T; Kamińska K; Lorenc-Koci E
Behav Brain Res; 2014 Mar; 261():79-88. PubMed ID: 24361083
[TBL] [Abstract][Full Text] [Related]
55. An animal model mimicking pedunculopontine nucleus cholinergic degeneration in Parkinson's disease.
Pienaar IS; Harrison IF; Elson JL; Bury A; Woll P; Simon AK; Dexter DT
Brain Struct Funct; 2015 Jan; 220(1):479-500. PubMed ID: 24292256
[TBL] [Abstract][Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
